Fig 1.
*Administrative problems defined as non-compliant with study visit or non-compliant with study drug.
Table 1.
Patient Baseline Characteristics.
Fig 2.
Median percentage reduction in SEGA and renal angiomyolipoma volume over time.
Fig 3.
Proportion of patients with ≥50% reduction/improvement in SEGA, renal angiomyolipoma, or skin lesions.
* *Skin lesion response determined as partial or complete by Physician’s Global Assessment.
Table 2.
AEs by Preferred Term Regardless of Relationship to Study Drug and by Year of Emergence Occurring in ˃10% of Patients.